Cardiovascular Disease
Conditions
Keywords
Follow-Up studies, Biological Pacemakers, Telemedicine, Efficiency
Brief summary
The purpose of this research is to estimate the outcomes in health and cost of the follow-up of patients with pacemakers. The initial hypothesize of this study is that remote monitoring of pacemaker will show a best relation of outcomes in costs and effectiveness than the conventional follow-up in hospital.
Detailed description
Cardiovascular Diseases are a major cause of global morbidity and mortality, being responsible according to the World Health Organization of the 30% of overall mortality. Since 2001 that the first pacemaker of remote monitoring was implanted in Europe, more than 300,000 pacemaker have been implanted around the world. Despite this sharp expansion, the scientific evidence on economic evaluations of pacemaker with remote monitoring is very limited, and in our knowledge, studies including informal costs have not been conducted. In the field of cardiology, telemedicine allows consultations with patients through monitoring systems and remote communication analyzing the ongoing heart rates of people with pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy and subcutaneous Holter. The use of remote monitoring may save time and efforts to both healthcare professionals and patients, including their informal caregivers, reducing the number of follow up visits to the hospital and reducing the associated costs with patient follow-up, which will help to improve sustainability of healthcare services. During the 06 months of study, the patients with implant of pacemakers of both groups will be assessed of the same parameters, in 3 different moments (pre-implant and months 1, and 6 post-implantation). Pacemakers that are going to be used in the project: 1. Remote monitoring group: Biotronik Estella SR-T and DR-T & Biotronik Evia SR-T and DR-T. 2. Hospital monitoring group: St Jude Medical Endurity SR and DR & Sorin Reply 200 SR and DR. The study will estimate: 1) The Clinical features of the patients. 2) The effectiveness through of administration of Health-Related Quality of Life questionnaires and 3) Finally, hospital and informal costs of patients with pacemakers will be estimated by the researches.
Interventions
DEVICETelemedicine System
Telemedicine System is used in remote monitoring group
Sponsors
University of Tromso
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Be 18 years of age * Have a pacemaker implanted * Understand and be able to properly perform self-monitoring at home
Exclusion criteria
* Be participating in another study * Refuse to participate in the study * Have implanted a different cardiac device to the pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical features | 6 months | Selected variables from the medical history records: * Gender * Age * Indication for the implantation of the pacemaker. * Comorbidities * Pharmacological treatment * Vital signs * Pacemaker parameters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 6 months | * Number of patients with Adverse Events * Type of Adverse Events diagnosed |
| Consultations and Hospitalizations unscheduled | 6 months | Number of unscheduled visits and hospitalizations |
| Health-Related Quality of Life | 6 months | EuroQol-5Dimensions (EQ-5D) |
| Indirect cost | 6 months | Maintenance of the medical consultation (hospital): * Electricity * Cleaning * Furniture * Health fungible * Equipment investment |
| Informal costs | 6 months | Costs related to the care and displacements of patients to hospital: * Displacement costs to hospital * Accommodation costs * Cost of meals * Costs for caregivers |
| Direct costs | 6 months | Direct costs taken into account: * Pacemakers' costs (device implanted) * Hospitalizations' costs * Consultations' costs (hospital) * Prescribed medical transport's cost * Health personnel costs * Pharmaceutical costs |
Countries
Norway
Outcome results
None listed